



NEWS RELEASE

Transparency Information: OncoMethylome Sciences

Liege (Belgium) – Regulatory Release – September 12, 2008, 8:00 CET – OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) publishes required information in accordance with new transparency legislation (Belgian Act of May 2, 2007) on disclosure of major holdings in issuers whose shares are admitted to trading on a regulated Belgian market.

Status as of 1 September 2008

Basic data

Total capital: EUR 48 362 545.64

Total number of securities conferring voting rights: 11 808 822 shares

Total number of voting rights (the denominator): 11 808 822 (one voting right per share)

Supplementary data

Total number of bonds convertible into securities conferring voting rights: zero

Total number of outstanding warrants convertible into securities conferring voting rights: 248,959

Total number of voting rights that may result from the exercise of outstanding warrants: 448,895

Total number of shares without voting rights: zero

Notification thresholds set by the Articles of Association

According to article 14 of articles of association of OncoMethylome Sciences SA, the provisions of articles 6 through 17 of the Act of May 2, 2007 apply not only to the legal thresholds of 5 % and of each multiple of 5%, but also to the threshold of 3%.

Information concerning the transparency legislation

Detailed information concerning the transparency legislation can be found in the Extract from the "*Guide to the Transparency Legislation CBFA_2008_16 of 8 July 2008*" which is available from the website of the Banking, Finance and Insurance Commission (CBFA):

www.cbfa.be/eng/gv/ah/circ/pdf/cbfa_2008_16.pdf

For submitting the notifications the CBFA recommends the use of its standard form TR-1 BE, which is also available from the CBFA website: www.cbfa.be/eng/gv/ah/circ/pdf/TR-1BE.xls

The notifications should be transmitted to both OncoMethylome Sciences SA and the CBFA. The CBFA recommends transmitting the notifications first electronically, to the e-mail address trp.fin@cbfa.be, and subsequently – for reasons of legal certainty – by fax to number + 32 2 220 59 12.

It is recommended to transmit notifications to OncoMethylome Sciences SA to the attention of:

Mr. Philip Devine, CFO
E-mail address: ir@oncomethylome.com
Fax: +32 4 364 20 84

About OncoMethylome Sciences

OncoMethylome Sciences SA (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Merck KGaA, and Millipore Corporation's BioScience Division. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

For more information please contact:

Lucija Turcinov
Tel. +32-479-801-902
ir@oncomethylome.com

or visit: www.oncomethylome.com